UBX1325

UBX1325 has been studied in 6 papers since 2022: 3 trials in people, 3 reviews; 2 in the past year. The newest paper, May 6, 2026: “Single-cell insights into maladaptive endothelial plasticity and therapeutic targets in diabetic vascular complications”.

InterventionSenolytics

6 papers study it8 findingsUpdated

PubChem

See all 6 papers on UBX1325

At a glance

The findings reach people, from one lab or study. 2 independent labs in 2 countries; 3 trials, 2 about aging.

“the difference between UBX1325 and sham in mean change to week 48 in best corrected visual acuity was 5.6 more ETDRS letters (95% confidence interval, -1.5 to 12.7)”
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular EdemaNEJM evidence2025doi:10.1056/evidoa2400009

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 2 independent labs in 2 countries
  • 3 trials, 2 about aging
  • 7 of 7 findings with company ties
  • 3 of 3 trials sponsored by its developers
  • Human trial3

Studies in people

2 studies gave UBX1325 to people and measured what changed.

What changedDesignPeopleSource

up: Increases best-corrected visual acuity5.6 more ETDRS letters vs sham (95% CI -1.5 to 12.7)

no change: Has no effect on treatment discontinuation due to treatment-emergent adverse events

no change: Has no effect on vital signs, electrocardiograms and routine blood chemistries

Randomized trialweek 4865 peopleBothDiabetic macular edema with prior suboptimal response to anti-VEGF treatmentNEJM evidence, Apr 22, 2025

up: Improves best-corrected visual acuity+6.2 ETDRS letters at Week 8, p = 0.02

up: Improves mfERG N1-P1 response density+14% at Week 8

Treated cohort48 weeks5 peopleNAMD subjects with active disease despite treatmentJournal of clinical medicine, Sep 19, 2024

What did studies of UBX1325 find?

7

Studies of UBX1325 measured 7 outcomes, among them best-corrected visual acuity, endothelial-to-mesenchymal transition and Vital signs, electrocardiograms and routine blood chemistries.

Best-corrected visual acuity

upin humans1

1 study
  1. UBX1325 increases best-corrected visual acuity in neovascular AMD subjects with prior anti-VEGF injections (+5 letters at Week 4 (p = 0.02); +6.2 letters at Week 8 (p = 0.02)).

    “The mean change in BCVA demonstrated statistical significance in Weeks 4 and 8, showing increases of 5 (p = 0.02) and 6.2 (p = 0.02) letters, respectively.”

    Human trialin neovascular AMD subjects with prior anti-VEGF injections50 μL intravitreal injectionn = 5

    Multifocal Electroretinography Changes after UBX1325 (Foselutoclax) Treatment in Neovascular Age-Related Macular Degeneration

    Journal of clinical medicine

  2. UBX1325 improves best-corrected visual acuity in humans (+6.2 ETDRS letters at Week 8, p = 0.02).

    “Mean change in BCVA demonstrated statistical significance at Weeks 4 and 8, showing increases of 5 (p = 0.02) and 6.2 (p = 0.02) ETDRS letters, respectively.”

    Human trial48 weeksn = 5

    Multifocal Electroretinography Changes after UBX1325 (Foselutoclax) Treatment in Neovascular Age-Related Macular Degeneration

    Journal of clinical medicine

endothelial-to-mesenchymal transition

downin reviews1

1 study
  1. UBX1325 prevents endothelial-to-mesenchymal transition (proposed in combination with TGF-β or SETD7 inhibition).

    “coupling senolytics, such as UBX1325, with anti-fibrotic strategies like TGF-β or SETD7 inhibition to prevent irreversible EndoMT”

    Reviewproposed in combination with TGF-β or SETD7 inhibition

    Single-cell insights into maladaptive endothelial plasticity and therapeutic targets in diabetic vascular complications

    Cardiovascular diabetology

Vital signs, electrocardiograms and routine blood chemistries

no changein humans1

1 study
  1. UBX1325 showed no clear effect on vital signs, electrocardiograms and routine blood chemistries in humans.

    “There were no apparent between-group differences with respect to vital signs, electrocardiograms, or routine blood chemistries.”

    Human trial10 μg single intravitreal injectionup to 48 weeksn = 65

    Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema

    NEJM evidence

Treatment discontinuation due to treatment-emergent adverse events

no changein humans1

1 study
  1. UBX1325 showed no clear effect on treatment discontinuation due to treatment-emergent adverse events in humans.

    “In this sham-controlled trial there were no TEAEs that led to discontinuation of treatment with UBX1325 compared with sham.”

    Human trial10 μg single intravitreal injectionup to 48 weeksn = 65

    Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema

    NEJM evidence

Best-corrected visual acuity

upin humans1

1 study
  1. UBX1325 increases best-corrected visual acuity in humans (diabetic macular edema with prior suboptimal response to anti-VEGF treatment) (5.6 more ETDRS letters vs sham (95% CI -1.5 to 12.7)).

    “the difference between UBX1325 and sham in mean change to week 48 in best corrected visual acuity was 5.6 more ETDRS letters (95% confidence interval, -1.5 to 12.7)”

    Human trialdiabetic macular edema with prior suboptimal response to anti-VEGF treatment10 μg single intravitreal injectionweek 48n = 65

    Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema

    NEJM evidence

More on Best-corrected visual acuity

Multifocal electroretinography N1-P1 response density

upin humans1

1 study
  1. UBX1325 increases multifocal electroretinography N1-P1 response density in neovascular AMD subjects with prior anti-VEGF injections (≥20% gain in three of five subjects at Week 8).

    “After foselutoclax treatment, the largest improvement in the mfERG N1-P1 response density occurred at Week 8 as three of five subjects achieved a ≥20% gain.”

    Human trialin neovascular AMD subjects with prior anti-VEGF injectionsretina50 μL intravitreal injectionn = 5

    Multifocal Electroretinography Changes after UBX1325 (Foselutoclax) Treatment in Neovascular Age-Related Macular Degeneration

    Journal of clinical medicine

More on Multifocal electroretinography N1-P1 response density

mfERG N1-P1 response density

upin humans1

1 study
  1. UBX1325 improves mfERG N1-P1 response density in humans (+14% at Week 8).

    “The total N1-P1 response density did not reach statistical significance at any visit but did have a noteworthy gain of 14% at Week 8 compared to baseline.”

    Human trial48 weeksn = 5

    Multifocal Electroretinography Changes after UBX1325 (Foselutoclax) Treatment in Neovascular Age-Related Macular Degeneration

    Journal of clinical medicine

More on mfERG N1-P1 response density

Has UBX1325 been tested in people?

2 of 3 about aging

Yes: 3 trials in people have been published.

Who is developing UBX1325?

1 company: Unity Biotechnology.

Companies
  • Unity BiotechnologyPhase 2neovascular age-related macular degeneration, diabetic macular edema

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 02 papers in 12 months